The true strength of Shockwave Medical is a remarkable team of talented individuals with decades of experience in the medical device industry. Passionate, ethical, and focused, we are dedicated to developing technologies that enable interventionalist to raise the standard of how advanced cardiovascular disease is treated.
If this sounds like something you would want to be part of, consider working with us.
Mr. Hawkins began his career in marketing and business development roles for Advanced Cardiovascular Systems, Inc. (Abbott Vascular). Following ACS, he held senior roles in general management, marketing and business development with a number of private and public companies. He started the marketing department at Intuitive Surgical (ISRG) where he guided product feature development for the DaVinci surgical robot and developed key foundational marketing strategies for the company. He has also held senior leadership and/or founder roles with Endologix, Inc. (ELGX), Calibra Medical Inc. (JNJ) and Shockwave Medical, Inc. Mr. Hawkins is the primary inventor of Lithoplasty® and served as CEO of Shockwave Medical from 2012 to 2017.
Mr. Hawkins has a MBA from Stanford, a BS in Economics from Wharton and is a named inventor on over 100 patents and applications.
In 1968, Mr. Adams started his career in design engineering for Honeywell Inc., designing timer circuits for land mines. In 1970, he transitioned from land mines and into the design of pacemakers for Medtronic. He served as their Manager of Pacemaker Electrical and IC Design for seven years. Following Medtronic, Mr. Adams held a variety of senior and managerial roles for a number of companies while also serving as founder for a majority of them. More specifically, he helped develop the first implantable atrial defibrillator at InControl and also the first automatic personal defibrillator at Physio-Control. From 2006-2007, Mr. Adams joined Seattle Medical Technologies and founded Calibra Inc. where he assisted in the development of a mechanical wearable insulin pump called “Finnese.” Shortly after, he founded Aspen Medtech Inc. in 2007, now called Shockwave Medical Inc., with partner Daniel Hawkins. He is currently serving as their Chief Technology Officer.
Mr. Adams has over 135 issued patents and pending patent applications to his credit , and is the author of six scientific publications. He holds a BSEE with distinction from the University of Minnesota.
Founder: Myometrix, InControl (INC), EndoGastric Solutions (CEO), Archus Orthopedics, Cardiac Dimensions, Calibra Medical (JNJ), Aspen Medtech Inc. (became Shockwave Medical Inc. in 2008)
Todd Brinton, M.D.
Dr. Brinton is a Clinical Associate Professor of Medicine (Cardiology) and Consulting Associate Professor of Bioengineering at Stanford University. He is an attending general and interventional cardiologist at both Stanford University Medical Center and the Palo Alto VA Medical Center. He has served as the fellowship director for the Stanford Program in Biodesign since 2005 and also co-directs both the executive education program in innovation management and the Stanford graduate course series in biodesign innovation.
Dr. Brinton completed his medicine, cardiology, and interventional training at Stanford University. He holds an MD from the Chicago Medical School and a BS in bioengineering from the University of California, San Diego. Along with Shockwave medical, he is co-founder and board director for BioParadox, Inc., another venture-backed medical device company in the cardiovascular space. He was a board director for Infogard laboratories until its acquisition in 2015 (Underwriter’s Laboratories) and was responsible for the early feasibility and clinical development programs for both Kona Medical and Qool Therapeutics. Additonally, he serves on the advisory board of a number of early-stage medical device companies where he focuses on clinical development and strategy. Prior to medical school he was the Clinical Research Director for Pulse Metric, Inc., a medical device start-up company.
President & Chief Executive Officer
Doug Godshall was most recently the Chief Executive Officer and a director of HeartWare International, Inc., a leader in the LVAD market where he served for 10 years until the company was acquired by Medtronic in August of 2016 for $1.1B. Prior to HeartWare, he held various executive and leadership positions at Boston Scientific, including President of the Vascular Surgery Division, a member of Boston Scientific’s Operating Committee and had previously served as Vice President, Business Development where he was responsible for more than 70 transactions, many of which were in the arenas of coronary and peripheral interventions. Mr. Godshall holds an M.B.A. from Northeastern University and a BA in Economics from Lafayette College.
Rob Williamson, Jr.
VP of Sales
Prior to joining Shockwave, Rob spent the majority of his 20 year device career in the vascular space. Most recently, Rob served in a Sales Director position for Zoll in their Cardiac Management Solutions division, and prior to that, Rob served as a Director and Vice President with Medtronic (formerly Covidien) in their Peripheral Vascular division. He has also served in sales and sales leadership positions with C.R. Bard, FoxHollow and ev3. Rob holds a B.A. from Auburn University.
Chief Financial Officer
Prior to Shockwave Medical, Mr. Puckett served as Chief Financial Officer for Counsyl, a venture backed DNA testing and genetic counseling company. From 2011 to 2015 he served as Chief Financial Officer for Ariosa Diagnostics, a molecular diagnostics company (acquired by Roche in 2015). Mr. Puckett came to Ariosa from Forest Laboratories where he served as Executive Director, Operations of Cerexa, a Forest Laboratories subsidiary. While at Cerexa, Mr. Puckett was part of the leadership team that was responsible for obtaining FDA approval for the drug Teflaro. Prior to Cerexa, he held senior finance and operations positions at Affymetrix, AOL, Viad, and BHP Billiton. Mr. Puckett holds an M.B.A. from the University of San Francisco and a B.A. degree in Accounting from Washington State University.
VP of Clinical Affairs
Prior to Shockwave Medical, Beaux served as Senior Director of Clinical Research at Medtronic’s Aortic and Peripheral Vascular business unit. During his 12 year tenure, he led clinical programs which introduced multiple aortic stent graft platforms into the U.S. and Japanese markets. Most recently, he was responsible for the global peripheral program, which included the successful launch of drug-coated balloons in the U.S., along with global expansion in additional geographies. Beaux holds a B.S. in Allied Health from Ohio State University and an M.B.A. from Georgia State University.
VP of Regulatory Affairs and Quality Assurance
Nora Hadding joined Shockwave Medical in July 2015. She has over 20 years’ experience in Regulatory Affairs and Quality Assurance for the medical device industry, working with both large corporations as well as small start-up companies. Nora’s experience includes bioresorbable vascular scaffolds, drug-eluting and bare metal coronary and peripheral vascular stents, carotid stents, embolic protection systems, coronary and peripheral balloon dilation catheters and guidewires, femoral artery closure devices, implantable devices for mitral valve regurgitation, hypothermia therapy, and neurostimulation and cardiac rhythm management devices. Prior to joining Shockwave Medical, Nora held regulatory leadership positions at Abbott Vascular, Inc., BeneChill, Inc., and Myocor, Inc. Nora’s additional experience includes Medtronic, Inc. and consulting to medical device companies. Nora holds a J.D. from the University of Oklahoma and a B.A. from the University of Minnesota, Minneapolis.
VP of Marketing
Rob joined Shockwave Medical from Medtronic where he was Chief Commercial Officer and then Managing Director for a startup joint venture whose aim was to expand access to modern acute cardiovascular care in a major emerging market through a public private partnership, a flagship strategic alliance for the company. Prior to that he was Senior Director of Global Marketing, leading the marketing function in Medtronic’s interventional cardiology franchise through a period of 30% growth to $1.8B in revenue. Rob has over 18-years of experience in interventional cardiology, holding positions in marketing, sales, business development and R&D. He holds a B.S. in Chemical Engineering from the University of Florida and M.B.A. from the Kellogg School of Management at Northwestern University.